Berlin Börse takes over Equiduct

Daily news headlines

LONDON – the Berlin Stock Exchange has acquired Equiduct. Equiduct and Börse say the move marks a repositioning for compliance with the November deadline for the Markets in Financial Instruments Directive (Mifid) and to take advantage of the European directive’s impact to provide best execution. Equiduct, the trading name for Easdaq, will offer the first Mifid-compliant, integrated pan-European point of connectivity for trading services through Börse Berlin’s regulated market.

Equiduct brings to the deal a market model that relies upon an up-to-date electronic trading system, delivering a fast turnaround time. “Over the last year we have implemented Mifid-specific requirements in close collaboration with various buy- and sell-side firms across Europe,” says Rob Brouwer, Equiduct’s chief information officer. The Berlin Stock Exchange runs as a regulated market, with a broad range of securities and experience in secondary exchange trading. Both parties maintain that the partnership will be suited to competition in the post-Mifid European market.

“Financial market participants are facing drastic changes as a result of new Mifid requirements, which we believe will finally create a competitive level playing field for exchanges and trading facilities. In the future, customers will have the right to demand best execution from their intermediary. Best execution will require that the intermediary takes into account all execution venues, instead of just the domestic exchange,” says Artur Fischer, Börse Berlin’s executive director of strategy.

  • LinkedIn  
  • Save this article
  • Print this page  

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: